Medical Devices

What sets us apart is the cross-talk between our engineers, our life scientists, our polymer chemists and our regulatory experts

Medical devices

The pre-eminent team for medical device patent counselling anywhere in Europe

Whether it’s building and defending a large patent portfolio for drug delivery technology, enforcing our client’s rights against surgical device copies, or managing Europe’s largest patent portfolio of orthopaedic equipment, our sector experience is unrivalled.

Our broad technical expertise is frequently needed to assess freedom to operate across large medical device patent portfolios. Our continued success in opposition proceedings means that we are regularly called upon to advise clients on how to acquire enhanced patent protection in new device areas.

We are routinely brought in to take over commercially significant cases and, with our combined litigation and technical experience, to resolve disputes. We are particularly adept at advising on product extension mechanisms through the attainment of device patent protection. Put simply, our experience in the sector is unsurpassed.

Senior Associates
Technical Assistants

Enforcement and defence of multiple European patents for Align Technology

Carpmaels & Ransford acted for Align Technology in its long running dispute with ClearCorrect in relation to Align’s well-known dental technology Invisalign.

The team, which included litigators and patent attorneys, handled patent infringement litigation before the UK High Court while defending Align’s European patents in opposition appeal proceedings before the Board of Appeal. The team also acted as EU coordinating counsel with a particularly active role on the parallel related EPO proceedings.

Carpmaels & Ransford successfully defends Arc Medical’s IP rights in the High Court

Carpmaels & Ransford acted for Arc Medical in relation to patent revocation claims and infringement issues concerning its medical device products ENDOCUFF® and ENDOCUFF VISION®.

The team defended Arc’s rights in the High Court which went on to find that all of Arc’s IP rights were valid and that the majority of them had been infringed by its competitor Cantel.